Skip to main content

Fluidigm’s Singapore Manufacturing Facility Reaches Full Throttle Ahead of Schedule

NEW YORK (GenomeWeb News) – Fluidigm yesterday said that its manufacturing facility in Singapore has begun working at full process ahead of schedule.
The facility, which opened its doors less than one year ago, was to reach this level by the end of 2006, a Fluidigm spokesperson said.
The facility manufactures BioMark dynamic arrays, among other products, which are integrated fluidic circuits that are designed to increase qPCR efficiency. Fluidigm will sell these products to study genetic and protein biomarkers.
Other chips currently being developed “address multi-step processes on a nanovolume scale, including synthesis of imaging probes used in positron emission tomography and the preparation of nucleic acids for analysis,” Fluidigm said in a statement.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.